HC comparative bioavailability conduct guidance
Conduct and Analysis of Comparative Bioavailability Studies
Current edition
Adopted 2012/02/08, revised 2023/01/30, effective 2018/09/01
Current edition
Adopted 2012/02/08, revised 2023/01/30, effective 2018/09/01
About this standard
Describes how comparative bioavailability and bioequivalence studies are planned, run, analyzed and reported, including subjects, design, food and fluid, sampling, bioanalysis and statistics. Parts for immediate-release products were replaced by ICH M13A from December 27, 2025.
Recognition by market
Whether the market recognizes, harmonizes or adopts this standard, and which edition it accepts
No market listing is published yet.
Testing requirements that cite it
Open the market page and its pathway pages for the full requirement, protocol and report content
Canada
- Biowaivers: BCS-based waivers and additional strengthsBioequivalence · Not stated
- Design and conduct of comparative bioavailability and bioequivalence studiesBioequivalence · Not stated
- Where the study can be done: foreign studies, GCP and facilitiesBioequivalence · Not stated
Related standards: JP guideline for bioequivalence studies of generic products, MHRA comparator product guidance, CPMP/EWP/QWP/1401/98 Rev 1, JP BE guideline, formulation changes (oral solid), NMPA Notice 2016 No. 61, Annex 3, FDA BE guidance for ANDAs (PK endpoints), NMPA Notice 2016 No. 61, Annex 1, HC comparative bioavailability standards, HC foreign-sourced reference product guidance, HC proportional formulations policy, M9, M13A. See all standards.